[이코노믹리뷰=황진중 기자] The Ministry of Food and Drug Safety has approved the phase 1 clinical trial of a domestic company inno.N for a COVID-19 vaccine.
The Ministry of Food and Drug Safety announced on the 22nd that it had approved a phase 1 clinical trial plan to evaluate the safety and immunogenicity of the domestically developed COVID-19 vaccine ‘IN-B009’.
With this approval, the number of drugs currently undergoing clinical trials related to COVID-19 in Korea has increased to 23, including 10 vaccines and 13 treatments (11 ingredients).
IN-B009 is a recombinant vaccine that injects the surface antigen protein of the Corona 19 virus into the human body by genetic recombination technology. Novavax’s COVID-19 vaccine, which is undergoing phase 3 clinical trials in the United States, was developed in this way.
IN-B009 strain was developed so that the protein can be delivered well into cells by additionally expressing a cell penetrating peptide (CPP‧Cell Penetrating Peptide) at the N-terminal portion of the surface antigen protein.
The Ministry of Food and Drug Safety said, “We will do our best to support the development of safe and effective COVID-19 treatments and vaccines so that our people can prevent diseases and receive treatment opportunities.”